Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ONCY Oncolytics Biotech	$0.75 +4.3%	$0.52	$0.33 ▼ $1.53	$70.77M	0.71	654,833 shs	1.59 million shs
QNTM Quantum Biopharma	$21.72 +2.8%	$13.92	$2.70 ▼ $38.25	$63.15M	0.55	937,409 shs	297,615 shs
VNRX VolitionRx	$0.84 -3.5%	$0.56	$0.40 ▼ $0.94	$86.30M	1.07	205,043 shs	139,410 shs
VRCA Verrica Pharmaceuticals	$0.52 -10.3%	$0.55	$0.38 ▼ $8.98	$48.34M	1.75	600,296 shs	3.89 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ONCY Oncolytics Biotech	0.00%	+8.77%	+105.98%	+25.10%	-27.83%
QNTM Quantum Biopharma	0.00%	-37.94%	+72.66%	+153.74%	+2,171,999,900.00%
VNRX VolitionRx	0.00%	-8.95%	+71.62%	+52.31%	+32.97%
VRCA Verrica Pharmaceuticals	0.00%	-10.64%	-4.09%	+20.69%	-92.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ONCY Oncolytics Biotech	2.1491 of 5 stars	3.4	3.0	0.0	0.0	3.8	0.0	0.0
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	1.6364 of 5 stars	3.5	0.0	0.0	0.0	0.6	2.5	0.0
VRCA Verrica Pharmaceuticals	4.0322 of 5 stars	3.1	1.0	0.0	4.7	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	477.32% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A
VNRX VolitionRx	3.00	Buy	$3.50	317.81% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	1,430.81% Upside

Current Analyst Ratings Breakdown

Latest QNTM, ONCY, VRCA, and VNRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/9/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	VNRX VolitionRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$2.50 ➝ $2.50
4/8/2025	VRCA Verrica Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/31/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$4.54 per share	N/A
VNRX VolitionRx	$1.31M	65.96	N/A	N/A	($0.11) per share	-7.62
VRCA Verrica Pharmaceuticals	$7.57M	6.39	N/A	N/A	($0.11) per share	-4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)
QNTM Quantum Biopharma	-$14.20M	-$15.98	N/A	N/A	N/A	N/A	-155.20%	-94.90%	8/13/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A
VRCA Verrica Pharmaceuticals	-$76.58M	-$1.20	N/A	N/A	N/A	N/A	N/A	-145.63%	8/13/2025 (Estimated)

Latest QNTM, ONCY, VRCA, and VNRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ONCY Oncolytics Biotech	N/A	3.20	3.20
QNTM Quantum Biopharma	N/A	0.96	0.95
VNRX VolitionRx	N/A	0.22	0.22
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ONCY Oncolytics Biotech	6.82%
QNTM Quantum Biopharma	1.24%
VNRX VolitionRx	8.09%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
ONCY Oncolytics Biotech	0.10%
QNTM Quantum Biopharma	8.53%
VNRX VolitionRx	10.40%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A
VNRX VolitionRx	80	103.02 million	80.80 million	Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	42.55 million	Optionable

QNTM, ONCY, VRCA, and VNRX Headlines

Recent News About These Companies

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27 at 7:35 PM | news.bloomberglaw.comN

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

June 19, 2025 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Consensus PT from Analysts

June 19, 2025 | americanbankingnews.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest

June 18, 2025 | marketbeat.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Brokerages

June 16, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's Why

June 10, 2025 | marketbeat.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 9, 2025 | aaii.comA

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

In face of U.S. stock market selloff, shares of West Chester firm are on the rise

April 8, 2025 | bizjournals.com

Verrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1

April 8, 2025 | markets.businessinsider.com

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ONCY, VRCA, and VNRX Company Descriptions

Oncolytics Biotech NASDAQ:ONCY

$0.75 +0.03 (+4.25%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.00 (+0.59%)

As of 06/27/2025 07:54 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Quantum Biopharma NASDAQ:QNTM

$21.72 +0.60 (+2.84%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.62 -0.11 (-0.48%)

As of 06/27/2025 07:56 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

VolitionRx NYSE:VNRX

$0.84 -0.03 (-3.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.87 +0.03 (+3.98%)

As of 06/27/2025 08:00 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.52 -0.06 (-10.28%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.05 (+8.88%)

As of 06/27/2025 05:50 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time